Anticoagulant treatment in patients with atrial fibrillation and ischemic stroke

Area of Science:

• Cardiology
• Neurology
• Public Health

Background:

• Atrial fibrillation (AF) is a common cardiac arrhythmia and a major risk factor for ischemic stroke.
• The lifetime risk of developing AF is 25%, highlighting its significant public health impact.
• Despite recognized risks, the effectiveness of recent treatment initiatives on stroke rates in AF patients remains under investigation.

Purpose of the Study:

• To evaluate whether increased treatment efforts over 15 years have reduced the proportion of ischemic stroke patients with known atrial fibrillation.
• To analyze trends in anticoagulant use and newly diagnosed AF among stroke patients.

Main Methods:

• Retrospective study including 4134 patients admitted with ischemic stroke between January 1997 and December 2012.
• Data collected from the Department of Neurology, Vejle Hospital, Denmark.
• Analysis included yearly proportions of patients with known AF, anticoagulant treatment rates, and newly diagnosed AF.

Main Results:

• The overall proportion of ischemic stroke patients with known AF remained stable, ranging from 9% to 18% (P = .511).
• A significant increase was observed in the proportion of known AF patients treated with anticoagulants (P = .002).
• The proportion of newly discovered AF cases also significantly increased during the study period (P = .035).

Conclusions:

• No significant reduction in the proportion of ischemic stroke patients with known AF was observed, despite increased anticoagulant use.
• Rising AF prevalence in the general population may be counteracting treatment improvements, leading to a stable proportion of AF-related strokes.
• Further research is needed to understand the interplay between AF prevalence, treatment, and stroke incidence.